摘要
目的探讨艾司西酞普兰联合心理干预治疗躯体形式障碍的临床疗效,并与单用艾司西酞普兰治疗进行比较。方法将135例躯体形式障碍患者随机分为研究组(n=68)和对照组(n=67)。研究组给予艾司西酞普兰联合心理干预治疗,对照组给予艾司西酞普兰治疗。2组于治疗前,治疗第2、4、8个周末采用症状自评量表(SCL-90)及多伦多述情障碍量表(TAS-26)进行疗效评定。结果研究组治疗第2个周末的SCL-90焦虑因子评分低于对照组,差异有统计学意义(P<0.05);治疗第4、8个周末,研究组SCL-90躯体化、抑郁、焦虑因子评分均低于对照组,差异均有统计学意义(P<0.05);治疗第8个周末,2组TAS-26评分均较治疗前下降,且研究组TAS-26评分较对照组低,差异有统计学意义(P<0.05)。结论艾司西酞普兰联合心理干预治疗躯体形式障碍疗效肯定,能显著改善预后,值得临床推广应用。
Objective To explore the clinical effect of escitalopram combined with mental intervention on the treatment of somatoform disorders and compare with the effect of single application of escitalopram. Methods A total of 135 patients with somatoform disorders were randomly divided into research group （ n = 68） and control group （ n = 67）. The research group was treated with combination therapy of escitalopram and mental intervention, while the control group was treated with escitalopram only. The efficacy was assessed by SCL-90 and TAS-26 before treatment and 2, 4 and 8 weeks after treatment. Results Two weeks after treatment, the score of anxiety of SCL-90 in the research group was lower than the control group, and there was significant difference between two groups （P 〈 0.05）. Four and 8 weeks after treatment, the scores of somatization, depression and anxiety of SCL-90 in the research group were lower than the control group, and there were significant differences between the two groups （P 〈 0.05）. Eight weeks after treatment, the scores of TAS-26 in both groups were significantly decreased, and the score of TAS-26 in the research group was significantly lower than the control group. There were significant differences between the two groups （P 〈 0.05）. Conclusion Escitalopram combined with mental intervention can treat somatoform disorders effectively and improve the prognosis significantly, so it is worthy of clinical application and popularization.
出处
《实用临床医药杂志》
CAS
2013年第9期54-56,共3页
Journal of Clinical Medicine in Practice
